Researchers at the University of Illinois at Chicago and Queensland University of Technology of Australia, have developed a device that can isolate individual cancer cells from patient blood samples.
The microfluidic device works by separating the various cell types found in blood by their size. The device may one day enable rapid, cheap liquid biopsies to help detect cancer and develop targeted treatment plans. The findings are reported in the journal Microsystems & Nanoengineering.
“This new microfluidics chip lets us separate cancer cells from whole blood or minimally-diluted blood,” said Ian Papautsky, the Richard and Loan Hill Professor of Bioengineering in the UIC College of Engineering and corresponding author on the paper. “While devices for detecting cancer cells circulating in the blood are becoming available, most are relatively expensive and are out of reach of many research labs or hospitals. Our device is cheap, and doesn’t require much specimen preparation or dilution, making it fast and easy to use.”
The ability to successfully isolate cancer cells is a crucial step in enabling liquid biopsy where cancer could be detected through a simple blood draw. This would eliminate the discomfort and cost of tissue biopsies which use needles or surgical procedures as part of cancer diagnosis. Liquid biopsy could also be useful in tracking the efficacy of chemotherapy over the course of time, and for detecting cancer in organs difficult to access through traditional biopsy techniques, including the brain and lungs.
However, isolating circulating tumor cells from the blood is no easy task, since they are present in extremely small quantities. For many cancers, circulating cells are present at levels close to one per 1 billion blood cells. “A 7.5-milliliter tube of blood, which is a typical volume for a blood draw, might have ten cancer cells and 35-40 billion blood cells,” said Papautsky. “So we are really looking for a needle in a haystack.”
Microfluidic technologies present an alternative to traditional methods of cell detection in fluids. These devices either use markers to capture targeted cells as they float by, or they take advantage of the physical properties of targeted cells — mainly size — to separate them from other cells present in fluids.
Papautsky and his colleagues developed a device that uses size to separate tumor cells from blood. “Using size differences to separate cell types within a fluid is much easier than affinity separation which uses ‘sticky’ tags that capture the right cell type as it goes by,” said Papautsky. “Affinity separation also requires a lot of advanced purification work which size separation techniques don’t need.”
The Latest on: Cancer blood test
via Google News
The Latest on: Cancer blood test
- Hormone Therapy for Prostate Cancer May Raise Heart Riskson November 20, 2020 at 3:46 pm
Hormone therapy can be a lifesaver for men with prostate cancer, but it also appears to put some at increased risk of heart problems, a new study reports. Long-term androgen deprivation therapy (ADT) ...
- Demario Davis' young daughter Carly-Faith is 'fully cancer-free,' latest tests showon November 19, 2020 at 3:10 pm
Five months after a rare cancer diagnosis, New Orleans Saints linebacker Demario Davis and his family had every reason to be optimistic regarding Carly-Faith's health status. Her blood test had ...
- Blood test reduces need for biopsy in lung canceron November 19, 2020 at 11:11 am
Advancements in treatment and diagnostics of lung cancer are helping patients live longer lives, even with advanced-stage disease.
- Blood test picks out cancers likely to benefit from targeted drugson November 17, 2020 at 6:36 am
A simple and inexpensive blood test could pick out patients with stomach or oesophageal cancer who are likely to benefit from targeted treatment, a new study shows.
- Blood test to detect cancer could see patients taken off toxic therapieson November 17, 2020 at 4:57 am
However the results can be a "crude" measure of cancer growth and can lead to unnecessary and harmful treatments. Scientists have been seeking an alternative that could allow patients' progress to be ...
- KDx Diagnostics And Lister Hospital Announce Exciting New Results With The Non-Invasive URO17™ Urine Test For Bladder Cancer In Hematuria Patientson November 16, 2020 at 7:21 pm
CAMPBELL, Calif. and STEVENAGE, England, Nov. 16, 2020 /PRNewswire/ -- KDx Diagnostics, Inc. (KDx), and Lister Hospital (East and North Hertfordshire NHS Trust), Stevenage, UK, announced today a joint ...
- Cheap blood test could help save or improve cancer patients’ liveson November 16, 2020 at 6:30 pm
A simple blood test could detect which cancer patients are likely to benefit from targeted treatment, research suggests. Patients with stomach or oesophageal cancer could be given a “liquid biopsy” ...
- InterVenn Biosciences raises $34 million to accelerate cancer test development with AIon November 16, 2020 at 2:06 pm
InterVenn Biosciences, a company developing an AI-imbued platform for diagnostic cancer test design, raised $34 million.
- Clinical Genomics Announces Medicare Coverage Applicable to COLVERA® (Liquid Biopsy Test to Detect Recurrence of Colorectal Cancer)on November 13, 2020 at 8:34 am
Updated coverage decision from Novitas Solutions marks major milestone, as Company advances toward full-scale commercializationBRIDGEWATER, N.J., Nov. 13, 2020 (GLOBE NEWSWIRE) -- (“CG” or the ...
- Study shows potential of new pinprick blood test for diagnosing HPV-related cancerson November 12, 2020 at 1:15 am
A potential breakthrough in the early detection of the neck, head and anal cancers linked to human papilloma viruses has emerged.
via Bing News